Trial
NCT01629667
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
MedImmune LLC
Collaborators
—
Condition
Idiopathic Pulmonary Fibrosis
Intervention
Tralokinumab
Why stopped
Early termination of the study due to lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-15